Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.74 |
| ▸ | RXRA | P19793 | 6/20 | 0.70 |
| ▸ | RXRB | P28702 | 6/20 | 0.70 |
| ▸ | RXRG | P48443 | 6/20 | 0.70 |
| ▸ | CA1 | P00915 | 3/20 | 0.64 |
| ▸ | CA2 | P00918 | 3/20 | 0.64 |
| ▸ | CA9 | Q16790 | 3/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.64 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6352494 | 0.91 | PTGS2 (0.74) | PTGS2CA1CA2CA9PTGS1 | |
| SCHEMBL8689127 | 0.90 | CA9 (0.79) | PTGS2RXRARXRBRXRGCA1 | |
| SCHEMBL6343529 | 0.89 | RXRA (0.66) | PTGS2RXRARXRBRXRGCA1 | |
| SCHEMBL14351136 | 0.89 | PTGS2 (0.74) | PTGS2RXRARXRBRXRGCA1 | |
| SCHEMBL6307479 | 0.89 | PTGS2 (0.77) | PTGS2CA1CA2CA9PTGS1 | |
| SCHEMBL6310403 | 0.87 | PTGS2 (0.74) | PTGS2CA1CA2CA9PTGS1 | |
| SCHEMBL213633 | 0.85 | PTGS2 (1.00) | PTGS2CA1CA2CA9PTGS1 | |
| SCHEMBL5547124 | 0.85 | RXRA (0.78) | PTGS2RXRARXRBRXRGSMN1; SMN2 | |
| SCHEMBL5551695 | 0.85 | RXRA (0.78) | PTGS2RXRARXRBRXRGSMN1; SMN2 | |
| SCHEMBL9522392 | 0.85 | RXRA (0.81) | PTGS2RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE44048-E1 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder | G.D. SEARLE LLC (US) | 2013-03-05 | — | — | US | disclosed |
| CN-101242875-A | Ophthalmic composition containing mucoadhesive polysaccharides capable of promoting corneal re-epithelialization | OPOCRIN SPA (IT) | 2008-08-13 | — | — | CN | disclosed |
| CN-100379727-C | Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation | SEARLE & CO (US) | 2008-04-09 | — | — | CN | disclosed |
| CN-1268614-C | Substituted pyrazolyl benzenesulfonamides for treating inflammation | SEARLE & CO (US) | 2006-08-09 | — | — | CN | disclosed |
| CN-1699347-A | Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation | SEARLE & CO (US) | 2005-11-23 | — | — | CN | disclosed |
| US-6951949-B2 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2005-10-04 | — | — | US | disclosed |
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2004-09-30 | — | — | US | disclosed |
| CN-1495170-A | Substituted pyrazolyl benzenesulfonamides for treating inflammation | G.D.ɪ����˾ | 2004-05-12 | — | — | CN | disclosed |
| US-6716991-B1 | REACTING ETHYL DIFLUOROACETATE AND 4'-CHLOROACETOPHENONE PRODUCING 4,4-DIFLUORO-1-(4-(CHLORO)PHENYL)-BUTANE-1,3-DIONE AND REACTING WITH 4-SULPHONAMIDOPHENYL HYDRAZINE HYDROCHLORIDE | G. D. SEARLE & CO. | 2004-04-06 | — | — | US | disclosed |
| US-6586603-B1 | Forming 4-(5-(4-chlorophenyl)-3-trifluoromethyl)-1H-pyrazol-1 -yl)benzenesulfonamide used as antiinflammatory agents; side effect reduction | G.D. SEARLE & CO. | 2003-07-01 | — | — | US | disclosed |
| US-6156781-A | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | G. D. SEARLE & CO. (US) | 2000-12-05 | — | — | US | disclosed |
| EP-0731795-B1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 1999-12-22 | — | — | EP | disclosed |
| CN-1202828-A | Substituted pyrzolyl benzenesulfonanides for use in veterinary | SEARLE & CO (US) | 1998-12-23 | — | — | CN | disclosed |
| EP-0854723-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1998-07-29 | — | — | EP | disclosed |
| US-5760068-A | NONSTEROIDAL ANTIINFLAMMATORY AGENTS WITH REDUCED SIDE EFFECTS | G.D. SEARLE & CO. (US) | 1998-06-02 | — | — | US | disclosed |
| US-5756529-A | ANTIINFLAMMATORY | G.D. SEARLE & CO. (US) | 1998-05-26 | — | — | US | disclosed |
| WO-1997011704-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1997-04-03 | — | — | WO | disclosed |
| CN-1141630-A | Substituted pyrazolyl benzenesulfonamides for treating inflammation | SEARLE & CO (US) | 1997-01-29 | — | — | CN | disclosed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | disclosed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | IL6, HRH4, CCR2 | PTGS2 279/4885RXRA 1088/4885RXRB 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.